Pharma BD Deal Intelligence
J&J / Crucell: Achieved Stated Rationale (Score: 75/100)
Full analysis, sources & comparables →J&J acquired Crucell for $2.4B as a vaccine center, later called Janssen Vaccines.
Johnson and Johnson completes tender offer for Crucell and declares offer unconditional acquiring the Dutch vaccine group to strengthen Janssen division.
Johnson and Johnson acquires vaccine developer Crucell with 58 percent premium to strengthen its biologics and vaccine pipeline capabilities.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
J&J acquired Crucell for $2.4B as a vaccine center, later called Janssen Vaccines.
J&J / Crucell: Achieved Stated Rationale (Score: 75/100)
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Crucell NV (this deal) | 2003 | $2.4B | 75 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2003 deals · Johnson & Johnson deals · Infectious Disease deals